Risk of urolithiasis due to topiramate as weight loss drug
Topiramate is sulfamate-substituted monosaccharide anti-epileptic and migraine drug, recently FDA approved as an anti-obesity medicine. Many reports of symptomatic urolithiasis with Topiramate usage as anti-epileptic and migraine drug are available including those studies with biochemical and stone risk profile. We present cases of symptomatic urolithiasis in patients on Topiramate for weight loss and to express caution that the drug usage should be limited and accompanied by assessment of risk profiles at regular intervals.
Reife, R., Pledger, G., Wu, S. C. Topiramate as add‐on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000; 41(Suppl 1): S66–S71.
Moradi S, Kerman SR, Mollabashi M. The effect of topiramate on weight loss in patients with type 2 diabetes. J Res Med Sci. 2013; 18(4): 297-302.
Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A, et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol. 2005; 96: 243–51.
Kou RL, Moran ME, Kim DH, Abraham HM, White MD, Lingeman JE. Topiramate induced nephrolithiasis. J Endourol. 2002; 16:229-31.
Wasserstein AG, Rak I, Reife RA. Investigation of Mechanistic basis for topiramate associated Nephrolithiasis: Examination of urinary and serum constituents. Epilepsia 1995; 39 Suppl 3): S153.
Welch BJ, Graybeal D, Moe O W, Maalouf N M, Sakhee Khashayar. Biochemical and Stone rick profiles with Topiramate treatment. Am J Kidney Dis 2006; 48(4): 555-563.
Warren BW, La Grange CA, Tucker T, Bensalem-Owen M, Pais VM Jr. Induction of Progressive profound hypocitraturia with increasing dose of topiramate. Urology 2008; 72: 29-32.
Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate. Epilepsia 1995; 3(suppl 3): S153.
Eggener S, Kim SC, User HM, Pazona J, Nadler RB. Urolithiasis associated with Topiramate. Int Braz J Urol. 2004: 30:29-31.
Copyright (c) 2019 International Journal of Biomedical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- An author must submit Copyright form After acceptance of the article.